A team of researchers from the United States and Sweden explored data from nearly 12,000 TAVR patients for a new systematic review and meta-analysis. 

A team of specialists tracked CT utilization before, during and after the 2022 shortage, sharing its findings in the American Journal of Neuroradiology.

Researchers have recently determined that the medication, originally developed to treat diabetes, can contribute to weight loss and reduce a patient's MACE risk by up to 20%. 

The CardioVascular Coalition and Society for Cardiovascular Angiography and Interventions have both issued new statements highlighting their issues with the 2024 MPFS proposed rule. 

New research, based on data from approximately 143 million patients, focused on prescriptions for heart failure, atrial fibrillation and other significant cardiac conditions. 

Teams from the Icahn School of Medicine at Mount Sinai and Weill Cornell Medicine will collaborate on the research. 

The FDA has said this is a Class I recall, which means using the devices “may cause serious injuries or death.” A total of 18 injuries have been reported so far.